Global CDMO scale Delpharm operates 18 industrial sites and 3 development centers across Europe and Canada, with a broad manufacturing footprint and capability to produce a wide range of dosage forms, presenting opportunities for cross-border fill-finish, packaging, and development partnerships.

Vaccine and biologics potential Historical collaborations with Pfizer and BioNTech for COVID vaccine fill-finish and ongoing development work indicate strong capabilities in high-demand, complex manufacturing, suggesting Upsell opportunities in vaccine, biologics, and sterile injectable programs.

Expanding facilities Recent and planned investments including a 140M facility upgrade in Canada and a 28M euro sterile line for prefilled syringes in France signal capacity expansion, creating opportunities to onboard new clinical-to-commercial programs and increased production scale for clients.

Clinical development support Delpharm offers comprehensive development services from phase 1 to 3 for solid, semi-solid, liquid, and injectable forms, enabling pharma clients to partner across development stages and streamline time-to-market for new therapies.

Strategic partnerships Past collaborations with BioNTech, Sandoz Canada, and Pfizer demonstrate a proven ability to execute with major players on complex, high-profile programs, suggesting credibility when pursuing larger enterprise deals and co-development opportunities.